Results 101 to 110 of about 31,387 (227)

Metastatic urothelial carcinoma of upper urinary tract [PDF]

American Journal of Hematology, 2007
Shau-Hsuan, Li, Wan-Ting, Huang, Ching-Yuan, Kuo   +2 more
openaire   +2 more sources

Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs

The Prostate, Volume 86, Issue 5, Page 568-581, April 2026.
ABSTRACT Background The dog is the only large mammal, other than humans, that commonly develops spontaneous prostate cancer (PCa) and is, therefore, considered a valuable model for comparative studies. Estrogens are critical for normal prostate development and contribute to prostatic carcinogenesis in men.
Jennifer Lothion‐Roy, Leonore Aeschlimann, Lea Anna Hiller, Sven Rottenberg, Nigel P. Mongan, Catrin S. Rutland, Emad Rakha, Alexander Dean, Mark A. Rubin, Simone de Brot   +9 more
wiley   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, Volume 65, Issue 4, Page 790-796, April 2026.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

What Is Your Diagnosis? Fine‐Needle Aspirate From a Lingual Mass in a Cat

Veterinary Clinical Pathology, EarlyView.
Emma Stacey, Andrii Trokoz, Kimberly Williams, Dorothee Bienzle   +3 more
wiley   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, Volume 20, Issue 3, Page 823-837, March 2026.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Scientific Reports
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic ...
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, María Natalia Gandur Quiroga, Elaine Lam, Deniz Tural, Lazar Popovic, Saul Campos-Gomez, Paolo Andrea Zucali, Augusto Mota, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Halima Abahssain, Andrea Benedetto Galosi, Giuseppe Badalamenti, Jindrich Kopecky, Aristotelis Bamias, Johannes Landmesser, Jawaher Ansari, Fabio Calabrò, Francesco Massari, Sebastiano Buti, Joaquim Bellmunt, Matteo Santoni   +29 more
doaj   +1 more source

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source

Metastatic Urothelial Carcinoma [PDF]

, 2020
openaire   +1 more source

Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody–drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial
Deema Sabtan, Marie‐Lisa Eich, Florian Loch, Julen Karl Pérez Zuschneid, Markus Möbs, Judith Böhme, Frederick Klauschen, David Horst, Mihnea P Dragomir, Gabriel Dernbach, Simon Schallenberg   +10 more
wiley   +1 more source